We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

58 hedge funds and large institutions have $1.04B invested in Ascendis Pharma A/S in 2017 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,200% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 2

250% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 6

71% more funds holding

Funds holding: 34 → 58 (+24)

61% more capital invested

Capital invested by funds: $646M → $1.04B (+$397M)

60% more funds holding in top 10

Funds holding in top 10: 5 → 8 (+3)

16.71% more ownership

Funds ownership: 71.6% → 88.3% (+17%)

Holders
58
Holders Change
+24
Holders Change %
+70.59%
% of All Funds
1.45%
Holding in Top 10
8
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+60%
% of All Funds
0.2%
New
26
Increased
21
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$18.5M
2
EC
EcoR1 Capital
California
+$17.9M
3
BBA
Baker Bros. Advisors
New York
+$17.1M
4
EAM
Eventide Asset Management
Massachusetts
+$16.2M
5
DM
Deerfield Management
New York
+$12.4M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$15.4M
2
ACP
Acuta Capital Partners
California
-$12.2M
3
RSCM
Rock Springs Capital Management
Maryland
-$1.29M
4
SFM
Sphera Funds Management
Israel
-$922K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$12.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
26
Driehaus Capital Management
Illinois
$3.6M +$2.85M +99,328 New
Deutsche Bank
27
Deutsche Bank
Germany
$3.36M +$1.61M +55,988 +153%
MIM
28
Monashee Investment Management
Massachusetts
$2.75M – – –
DCM
29
DAFNA Capital Management
California
$2.62M +$1.12M +39,012 +117%
Morgan Stanley
30
Morgan Stanley
New York
$2.44M +$761K +26,502 +65%
EU
31
Emory University
Georgia
$2.17M +$12.1K +421 +0.7%
MF
32
Magnetar Financial
Illinois
$1.41M +$1.12M +38,985 New
HI
33
HBK Investments
Texas
$1.27M +$1M +35,000 New
Renaissance Technologies
34
Renaissance Technologies
New York
$1.21M +$230K +8,030 +32%
AA
35
ALPS Advisors
Colorado
$1.16M +$76.5K +2,665 +9%
Wells Fargo
36
Wells Fargo
California
$1.09M +$766K +26,692 +789%
AllianceBernstein
37
AllianceBernstein
Tennessee
$1.09M +$861K +30,000 New
IHM
38
Iguana Healthcare Management
New York
$1.09M +$861K +30,000 New
Geode Capital Management
39
Geode Capital Management
Massachusetts
$723K +$8.21K +286 +1%
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$713K +$119K +4,158 +27%
State Street
41
State Street
Massachusetts
$679K +$538K +18,752 New
ECM
42
Endurant Capital Management
California
$628K +$497K +17,330 New
MS
43
Maven Securities
Jersey
$610K +$481K +16,757 New
Citadel Advisors
44
Citadel Advisors
Florida
$372K +$295K +10,273 New
SSA
45
Schonfeld Strategic Advisors
New York
$354K +$280K +9,763 New
Jane Street
46
Jane Street
New York
$352K +$278K +9,704 New
TI
47
Trexquant Investment
Connecticut
$320K +$918 +32 +0.4%
MC
48
Matisse Capital
Oregon
$311K – – –
AG
49
Aperio Group
California
$241K +$191K +6,659 New
BCM
50
BlueCrest Capital Management
Jersey
$226K +$179K +6,245 New
1
2
3

ASND Hedge Fund Activity: Q3 2017 in Review

58 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2017, worth a combined $1.04B — up 61% from $646M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ASND positions and 2 closed out — a net gain of 24 holders — while 21 added to existing stakes and 6 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $18.5M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $15.4M sold.

  • 58 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2017, up from 34 in Q2 2017.
  • Funds reported $1.04B of Ascendis Pharma A/S stock for Q3 2017, up 61% quarter-over-quarter.
  • 26 funds opened new Ascendis Pharma A/S positions in Q3 2017 and 2 closed out, a net change of +24 holders.
  • The largest Ascendis Pharma A/S buyer in Q3 2017 was Avoro Capital Advisors, an estimated $18.5M added.
  • The largest Ascendis Pharma A/S seller in Q3 2017 was Janus Henderson Group, an estimated $15.4M sold.

Based on aggregated 13F filings for Q3 2017.